Literature DB >> 7528472

Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 cases.

J R Goldblum1, H D Appelman.   

Abstract

Using cell size, cell density, and microscopic growth pattern, 20 duodenal stromal tumors were initially separated into benign and malignant categories. The 10 histologic benign tumors had uniform spindle cells, low cellularity, and an organoid pattern. All had round eosinophilic collagen blobs scattered among the spindle cells, were 4.5 cm or less in maximum diameter, and had two or fewer mitoses per 50 high-power fields (HPF). None metastasized or recurred during a median follow-up of 7 years. In contrast, the 10 histologically malignant tumors were highly cellular, all had two or more mitoses per 50 HPF, and all but one had diameters of 4.5 cm or greater, the exception being 4 cm. Eight cases also had benign-appearing areas, usually submucosal. Eight patients died with disease a median of 31 months after resection, almost all with liver metastases. One patient is alive with metastasis at 13 years. The patient with the 4-cm malignant tumor is disease free at 49 months. All 15 cases were strongly vimentin positive, 11 had S-100 protein, and seven had the CD34 marker. None were desmin or actin positive. No immunophenotype separated benign from malignant. The proliferation marker, proliferating cell nuclear antigen, correlated with histologic diagnosis and clinical outcome, but Ki-67 did not. Based on light microscopic features alone, benign and malignant duodenal stromal tumors can be separated from each other. Tumors with large cells and an organoid pattern are predictably benign; in this study, these tumors measured 4.5 cm or less in diameter and had fewer than 2 mitoses per 50 HPF. Highly cellular tumors with small cells and little or no organoid pattern are malignant. They usually have a diameter greater than 4.5 cm and more than two mitoses per 50 HPF, and they are usually fatal. Immunostaining for cytoplasmic proteins and proliferation markers offers no additional prognostic information to the light microscopic appearances. These conclusions apply only to duodenal tumors; whether they also apply to stromal tumors of the jejunum and ileum is not known.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7528472     DOI: 10.1097/00000478-199501000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

1.  Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach.

Authors:  Yoshinari Mochizuki; Yasuhiro Kodera; Seiji Ito; Yoshitaka Yamamura; Yukihide Kanemitsu; Yasuhiro Shimizu; Takashi Hirai; Kenzo Yasui; Ken-ichi Inada; Tomoyuki Kato
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

2.  Primary duodenal neoplasms: a retrospective clinico-pathological analysis.

Authors:  Amanjit Bal; Kusum Joshi; Kim Vaiphei; J D Wig
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

3.  Solitary intra-abdominal tuberculous lymphadenopathy mimicking duodenal GIST.

Authors:  You Sun Kim; Jeong Seop Moon; Jung Whan Lee; Il Kim; Soo Hyung Ryu; In Wook Paik
Journal:  Korean J Intern Med       Date:  2005-03       Impact factor: 2.884

Review 4.  The histopathological differential diagnosis of gastrointestinal stromal tumours.

Authors:  J F Graadt van Roggen; M L van Velthuysen; P C Hogendoorn
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

5.  GASTROINTESTINAL STROMAL TUMOURS.

Authors:  Kailash Chand; T Chatterjee
Journal:  Med J Armed Forces India       Date:  2017-06-08

Review 6.  [Gastrointestinal stromal tumors. A morphologic and molecular genetic independent tumor entity with new therapeutic perspectives].

Authors:  G Mechtersheimer; T Lehnert; R Penzel; S Joos; G Egerer; H F Otto
Journal:  Pathologe       Date:  2003-03-21       Impact factor: 1.011

7.  Feasibility and oncological outcomes of limited duodenal resection in patients with primary nonmetastatic duodenal GIST.

Authors:  Ahmed El-Gendi; Saba El-Gendi; Mohamed El-Gendi
Journal:  J Gastrointest Surg       Date:  2012-09-25       Impact factor: 3.452

Review 8.  The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution.

Authors:  Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2003-02-26       Impact factor: 4.064

9.  [Malignant gastrointestinal stromal tumor (GIST) of the papilla vateri. A rare tumor entity].

Authors:  K Wellmann; G Gohla; H Wenk
Journal:  Chirurg       Date:  2004-02       Impact factor: 0.955

10.  Elevated (> or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases.

Authors:  Claire Toquet; Jean Claude Le Néel; Louis Guillou; Karine Renaudin; Antoine Hamy; Marie-Françoise Heymann; Sophie Simon-Valla; Joël Le Borgne; Christine Maugard; Maryse Fiche
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.